Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
about
Mirtazapine versus other antidepressive agents for depressionSertraline versus other antidepressive agents for depressionFluvoxamine versus other anti-depressive agents for depressionMilnacipran versus other antidepressive agents for depressionReboxetine versus other antidepressive agents for depressionSertraline versus other antidepressive agents for depressionEscitalopram versus other antidepressive agents for depressionMirtazapine versus other anti-depressive agents for depressionVenlafaxine versus other anti-depressive agents for depressionDuloxetine versus other anti-depressive agents for depressionFluvoxamine versus other anti-depressive agents for depressionEscitalopram versus other anti-depressive agents for depressionMilnacipran versus other anti-depressive agents for depressionParoxetine versus other anti-depressive agents for depressionSingle-action versus dual-action antidepressantsTricyclic antidepressant pharmacology and therapeutic drug interactions updatedA review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdoseVenlafaxine for major depressionIs remission of depressive symptoms in primary care a realistic goal? A meta-analysisPharmacotherapy in depressed children and adolescentsThe other face of depression, reduced positive affect: the role of catecholamines in causation and cureComparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis of head-to-head randomized clinical trials.A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials.Treatment of pain syndromes with venlafaxine.Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients.Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysisTranscriptional evidence for the role of chronic venlafaxine treatment in neurotrophic signaling and neuroplasticity including also Glutamatergic [corrected] - and insulin-mediated neuronal processes.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Extended-release formulation of venlafaxine in the treatment of post-traumatic stress disorder.Efficacy comparison of duloxetine and SSRIs at doses approved in Japan.Profiling of Proteins Regulated by Venlafaxine during Neural Differentiation of Human CellsRecent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future.Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label studyAntidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells.Pharmacogenetics of monoamine transporters.
P2860
Q24234046-B2795AE6-8102-4218-ACF9-C9F1DD3FB5A9Q24235928-87CDAA95-EDCD-4890-A511-0C869D965719Q24236814-9F06C50F-E1C8-4A3E-8A09-B9410042BBE7Q24240125-B2C23A41-B9D4-4F75-A4B0-AD901077EE40Q24240504-CB5C2CDD-1B42-47E2-9E58-DBF15E583FB3Q24241023-58E1C10E-59BC-4E45-8B85-9EAC22472535Q24241065-65462485-1F5D-4921-A00D-4BB968A65720Q24245696-BCF4B61B-1D0F-40E3-93E7-A1333E0E4D99Q24245701-A07D016E-788C-4A58-9DA1-85F00A018C5AQ24245784-3BE4CE61-032E-4976-B0C1-B2239EB58E7EQ24245886-4EAF7CAD-206E-44D9-B97B-7C528C02A1BEQ24245921-F38BDF2E-553D-4298-8DEC-91D25DD86C14Q24246033-F4DD86B4-7EB9-4090-861C-88196AC4E1EEQ24246040-70049EE0-5576-4D11-9D69-E6D1D1D1AFB0Q24562551-97AF4B0C-47BC-4E04-A89A-EDC66C63385CQ24564967-D3CE2503-4B6B-44AA-9A45-4F448216F3D4Q24606269-8F6ED0F6-F854-496E-86F9-F3962115855FQ24678849-2CDC97C2-381B-412F-9E26-0DE6D2208FCAQ24794437-5D7CB0E4-F8A4-40BF-8F47-00BE3053988EQ28247623-6831BDAA-B7A0-4533-8947-DAF63BD23BDAQ28269179-82013690-0F90-45B2-873F-2CCFA69EF724Q33574107-5A436660-53A6-4475-A7EB-212A2F1E3AB6Q33689953-E18D8FDF-F30D-4428-9419-63BCFCD4C1F9Q33807834-9D92D025-7690-45D8-B006-CDB232B5FAF7Q34072466-F80EBB77-A416-4B09-8F24-A519AEB2A79CQ34163718-829A7951-ABC6-4E8A-902C-D913D8E8AD6BQ34322978-C1A82142-95AD-448D-AE1B-3DB912B5BEA7Q34355963-474A73EB-8840-4ADA-AA10-8FEA4A616631Q34384552-BF0D443E-299F-4018-B778-28C1DAF52A21Q34480541-900FE6D6-722A-45C9-B705-1BCD88641CD5Q34571919-36202858-B0E1-4572-8E14-1023318C5660Q34578945-462BD5FF-C1E4-456A-9531-FF97A8FC207EQ34590507-6A8CC1A8-2902-453D-863D-1551369468C0Q34636674-E331364E-2DEE-41D2-8369-26788FCE046EQ34977592-B75571DC-3F36-48B9-B1F3-AD867D2E8796Q35028372-243BF36F-C5AE-486F-B45E-E774E6580FD2Q35040802-7D05233A-D0BD-4501-B109-9E460DC01667Q35062660-977A7996-BDA3-4B6D-83F3-6ED4CF2E56D4Q35179051-9EF26CC2-1F03-4DBD-B126-DB06772D1C5FQ35207551-6EF0104F-E10E-4471-96A0-6AED0D9CEF14
P2860
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@ast
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@en
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@nl
type
label
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@ast
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@en
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@nl
prefLabel
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@ast
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@en
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@nl
P50
P356
P1476
Efficacy and tolerability of v ...... idepressants: a meta-analysis.
@en
P2093
Carrie Dempster
David Smith
P304
P356
10.1192/BJP.180.5.396
P407
P577
2002-05-01T00:00:00Z